Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Russia Signs MOU With U.S. Pharmacopeia To Improve Drug Quality

This article was originally published in PharmAsia News

Executive Summary

The Russian Ministry of Healthcare and Social Development (Minzdravsoc) and the U.S. Pharmacopeia Convention signed a memorandum of understanding to improve the quality of medicines in the Russian Federation

You may also be interested in...

Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States

Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia

Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop

Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration

After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration

BEIJING - After signing an agreement on cooperation with China's Center for Disease Control and Prevention in the wake of a series of contaminated drug and food scandals, leaders of the U.S. Pharmacopeial Convention are working to develop new tests that could be used to safeguard the global supply chain

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts